革命性IBD治疗:对当代治疗策略的洞察
Pooja Kushwaha1,2, Rahila Qureshi1, Nooruddin Khan3
1Laboratory of Molecular Cell Biology, BRIC-Centre for DNA Fingerprinting and Diagnostics (CDFD), Uppal, India.
International reviews of immunology
|September 30, 2025
概括
炎症性肠病 (IBD) 治疗有局限性和副作用. 基于的疗法通过调节炎症和促进愈合来管理IBD有希望.
科学领域:
- 胃肠道学和免疫学
- 药物发现和开发 药物发现和开发
背景情况:
- 全球炎症性肠病 (IBD) 患病率正在增加,这与城市化和生活方式的变化有关.
- 目前的IBD治疗方法如氨基酸盐,皮质类固醇,免疫调节剂,生物制剂,JAK抑制剂和抗生素可以控制症状,但具有显著的局限性.
- 限制包括副作用 (恶心,感染,肝脏毒性),耐药性,反应丧失,高成本 (生物制剂) 和免疫抑制剂的长期安全问题.
研究的目的:
- 批判性地评估现有的炎症性肠病 (IBD) 治疗方法及其局限性.
- 突出IBD管理中迫切需要创新的治疗策略.
- 探索基于的疗法的潜力,作为IBD的新方法.
主要方法:
- 对当前炎症性肠病 (IBD) 治疗方法的文献综述.
- 分析与传统疗法相关的局限性和副作用.
- 对IBD基于的治疗方法的临床前和临床研究的审查.
主要成果:
- 现有的IBD疗法虽然对一些患者有效,但存在一些挑战,包括副作用,耐药性和高成本.
- 很大一部分患者 (10-30%) 对当前的标准治疗没有充分的反应.
- 基于的疗法在预临床和临床环境中显示出调节炎症和促进粘膜愈合的潜力.
结论:
- 显然有对新型治疗策略的需求,以克服当前炎症性肠病 (IBD) 治疗的局限性.
- 基于的疗法是未来IBD管理的有希望的途径,因为它们具有抗炎和治疗性质.
- 需要进一步的研究和临床研究,以充分确定在IBD治疗中的作用.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
437
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
437
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
643
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
643
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492


